X4 Pharmaceuticals Appoints William E. Aliski to Board of Directors
CAMBRIDGE, Mass.–(BUSINESS WIRE)–X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the…
Pharmaceuticals, Biotechnology and Life Sciences
CAMBRIDGE, Mass.–(BUSINESS WIRE)–X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the…
WALTHAM, Mass.–(BUSINESS WIRE)–Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced its support…
Cerevel’s study of Tavapadon results demonstrated a statistically significant improvement in motor symptoms with once-daily dosing of oral tavapadon, which has enabled the company to plan on kicking off Phase 3 trials of tavapadon to fully characterize its potential benefit for patients with Parkinson’s disease.
International Liver Cancer Association (ILCA) is devoted exclusively to liver cancer research A Phase III study protocol for Namodenoson in…
–Rocket’s Largest Lentiviral Pipeline Opportunity with an Estimated Prevalence of 3,000 to 8,000 Patients in the U.S. and EU– –Phase…
– Results Suggest Additive or Synergistic Activity in Both Treatment Naïve and Previously Treated Patients – -Tivozanib-Nivolumab Combination Generally Well…
The U.S. Food and Drug Administration approved on Friday Novo Nordisk’s Rybelsus (semaglutide) oral tablets to improve control of blood sugar in adult patients with type 2 diabetes, along with diet and exercise.
Clovis to acquire rights to discovery program for three additional targets for radionuclide therapy Clovis to pay approximately $12 million…
Clinically meaningful improvement of 25 ETDRS letters equivalent versus nadir of BCVA in GS010-treated eyes at 96 weeks Results coherent…
Ipsen’s study of Dysport treatment of patients with personalized diary-based rehabilitation program improved patients’ voluntary movement as measured by a composite active range of motion (CXA) outcome.